
Releases
Compugen Targets 2027 Milestone as Cash Runway Extends to 2029
Clinical-stage immunotherapy firm Compugen Ltd. is positioning its lead candidate COM701 for a critical inflection point, with interim progression-free survival data from the MAIA-ovarian trial now slated for the first quarter of 2027. The company reports a stable financial foundation, with current reserves projected to fund operations through 2029.
























